Tag Archives: Pharmaceuticals

Hospitals, HHS each scored a win and a loss in recent Supreme Court cases

Photo by Geoff Livingston via Flickr.

Amid issuing some of the most significant rulings this century, the U.S. Supreme Court (SCOTUS) also decided on two cases where certain hospitals challenged federal decisions that cost them money. 

Hospitals scored one win and one loss in these cases. Both cases involved Department of Health and Humans Services (HHS) policies created under Republican presidents that the Biden administration sought to defend. 

In Health and Human Services Secretary (HHS) Becerra v. Empire Health Foundation, the Supreme Court split 5-4 in a June 24 decision about a calculation used to decide which hospitals qualify for extra pay for serving many people with low incomes. The Supreme Court found in favor of HHS in this case, disappointing hospital groups.

On June 15 in the American Hospital Association (AHA) v. Becerra case, the Court said in a unanimous decision that HHS erred in the administrative procedures in cutting reimbursement on certain drugs. In this case, the Biden administration had defended a Trump administration bid to compel hospitals to share certain savings they get on medicines with Medicare and people enrolled in the program.

Continue reading

Panel learns why there’s no easy fix for high drug prices

Photo: Pia Christensen/AHCJMartin Van Trieste

One of the best sessions at Health Journalism 2019 in Baltimore was the panel discussion about drug prices on May 3, “Of price spikes and shortages: New initiatives to increase patient access to generic and biosimilar drugs.” Wendy Wolfson, an independent journalist from Irvine, Calif., moderated the discussion.

Perhaps the most interesting of the four panel members was Martin Van Trieste, president and CEO, Civica Rx, a nonprofit manufacturer of generic drugs for hospitalized patients. Seven of the nation’s largest health systems have invested in Civica and their representatives will serve on its board of directors along with representatives from three philanthropies: the Laura and John Arnold Foundation, the Peterson Center on Healthcare, and the Gary and Mary West Foundation. Continue reading

ACA limits Medicare’s use of key value metric for drug prices

Health insurers are trying a wide variety of methods to link drug costs to the value medications deliver to patients. Value-based payment strategies bear watching for two reasons. First, they are aimed at controlling the high costs of prescription medications, and, second, they could usher in new ways of pricing all medications.

The idea that insurers should link a drug’s value to price is not new, but it is gaining traction, at least among private health plans. One proposal calls for paying for drugs based on the quality-adjusted life year, or QALY, a measure used to quantify the value of treatment. Continue reading

Looking ahead to reporting on aging in the new year

Photo by Boris Bartels via Flickr

Photo by Boris Bartels via Flickr

There are plenty of aging-related stories on the horizon for 2015. Here are just some issues and ideas to get you started:

The once-a-decade White House Conference on Aging is scheduled for sometime in mid-2015 – a date is yet to be finalized. It’s the 50th anniversary of Medicare, Medicaid, and the Older Americans Act, as well as the 80th anniversary of Social Security. The conference will focus on four key areas:

  • Retirement security
  • Healthy aging
  • Long-term services and supports
  • Elder justice

Look for plenty of updates on the conference by spring.


Issues include financial security, affordable housing, aging-in-place and community-based support services. According to Leading Age Magazine, boomers are poorly prepared when it comes to savings. How are the 50- and 60-somethings in your community preparing for retirement? Or are they? Continue reading

Researchers ‘owe’ the public information about financial ties #ahcj14

When writing about medical studies, reporters should always ask researchers about any financial relationships with drug companies or device manufacturers. That was one of the main lessons from a panel on conflicts of interest on Saturday at Health Journalism 2014.

Starting in September, sunshine provisions in the Affordable Care Act will require drug companies to disclose most payments to doctors. Some companies have already started to publicize their financial relationships with doctors. But most medical journal articles do not give accurate information on researchers’ potential conflicts of interest, said panelist Susan Chimonas of the Institute of Medicine as a Profession at Columbia University.

“You shouldn’t be uncomfortable asking these questions,” Chimonas said. “They owe you this information. They owe everyone this information.” Continue reading